Sun Pharmaceutical Industries stock
Price history
+8.21% over the period1 year: from ₹1,737.40 (November 13, 2025) to ₹1,880.00 (November 13, 2026), +8.21%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | ₹1,880.00 |
| October 30, 2026 | ₹1,777.70 |
| September 30, 2026 | ₹1,816.60 |
| August 31, 2026 | ₹1,984.80 |
| July 31, 2026 | ₹1,990.50 |
| June 30, 2026 | ₹1,862.50 |
| May 29, 2026 | ₹1,799.20 |
| April 30, 2026 | ₹1,808.30 |
| March 30, 2026 | ₹1,757.20 |
| February 27, 2026 | ₹1,737.00 |
| January 30, 2026 | ₹1,595.30 |
| December 31, 2025 | ₹1,719.70 |
| November 28, 2025 | ₹1,831.60 |
| November 13, 2025 | ₹1,737.40 |
At a glance
The company
Generic pharmaceutical company developing, manufacturing and marketing branded and generic formulations and active pharmaceutical ingredients across multiple therapeutic areas
Latest results
Quarter to September 30, 2026 · EPS ₹13.16 (estimate ₹12.89)
Next event
TickerLandia's take on Sun Pharmaceutical Industries
- Priced as usual relative to earnings: P/E on the latest fiscal year 39 vs a median of 39 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 41 vs 41 (+0%) in a group of 11.
- Strong point: Financial strength (75/100 in its group). Weak point: Growth (45/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−8.15% from the 52-week high
Analysts · 34 analysts
Average target₹2,111.94+12.34% vs. price
Buy 29 · Hold 1 · Sell 4 · Buy
TickerLandia Fingerprint: Sun Pharmaceutical Industries
Compared with similar companies: very low risk.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricehigh75
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 40.9 76 Forward P/E 29.7 73 EV/EBITDA 24.4 73 Price/book 5.01 75 Price/sales 7.27 77 Profitabilityhigh63
How much it earns on revenue and capital.
Metric Value Position in group ROE 13.1% 43 ROA 8.2% 67 Gross margin 79.3% 80 Net margin 17.8% 67 Operating margin 23.3% 59 Earnings stabilityhigh73
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.3% 83 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage45
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +10.03% 57 Earnings growth (year over year) −36.20% 26 Revenue growth (year over year) +11.90% 53 Financial strengthhigh75
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.56 80 Interest coverage 40.2 68 Debt/equitycounts in reverse: lower means more financial strength 0.04 82 Current ratio 2.94 72 Dividendaverage56
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 31 years 95 Payout ratio 35.0% 45 Dividend yield 0.9% 28 Market momentumstrong60
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +8.21% 53 Distance from 200-day average +3.19% 68 Riskvery low4
How much the price swings.
Metric Value Position in group Volatility (60 days) 18.7% 4 Maximum drawdown (12 months) 13.2% 3
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Sun Pharmaceutical Industries is priced as in the past and in line with similar companies
On the latest fiscal year's earnings (2026), Sun Pharmaceutical Industries's P/E today is 39.3, in line with the median of its last 10 fiscal years (39.3; between 22.5 and 67.3 from 2017 to 2026). Sun Pharmaceutical Industries's P/E (trailing 12 months): 40.9, in line with the median of a group of 11 similar companies (40.9).
Compared with 11 similar companies
| Metric | Sun Pharmaceutical Industries | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 40.9 | Middle | |
| Forward P/E | 29.7 | Middle | |
| Operating margin | 23.3% | Middle | |
| ROE | 13.1% | Low | |
| Debt/equity | 0.04 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Sun Pharmaceutical Industries. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
₹161.99B
Latest quarter · Q3 2026
Net income
₹19.89B
Latest quarter · Q3 2026
Quarterly net margin
12.3%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ₹4.48T
- P/E
- 40.9
- EPS
- ₹45.70
- Volume
- 1.3M
- Daily trading
- €40.54M
- Dividend yield
- 0.85%
- Last ex-dividend on July 7, 2026
How Sun Pharmaceutical Industries is changing
All resultsRevenue grew 11.8% a year on average over the last 5 years
Operating margin rose from 21.2% to 23.3%
Profits turn into cash: free cash flow equal to 96% of net income
Returns
Sun Pharmaceutical Industries returns with dividends
₹1,000 invested in Sun Pharmaceutical Industries 5 years ago, on November 15, 2021, would be worth ₹2,436 today with dividends reinvested: +143.57% in total, +19.51% per year. On price alone it would be ₹2,319 (+131.90%).
| Period | Sun Pharmaceutical Industries | ₹1,000 becomes |
|---|---|---|
| 1 month | +6.17% | ₹1,062 |
| 6 months | +3.02% | ₹1,030 |
| Year to date | +9.32% | ₹1,093 |
| 1 year | +9.19% | ₹1,092 |
| 3 years | +63.99% | ₹1,640 |
| 5 years | +143.57% | ₹2,436 |
| 10 years | +200.23% | ₹3,002 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Sun Pharmaceutical Industries: technical analysis
Sun Pharmaceutical Industries shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 6.1% below its all-time closing high (₹2,001.10, July 30, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 64
- Between 30 and 70
- vs 200-session average
- +3.19%
Active signals
Death cross: the 50-session average has crossed below the 200-session average.
since November 11, 2026
Support and resistance
Price areas where Sun Pharmaceutical Industries has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance₹1,903.50+1.25%3 touches, last on September 21, 2026
- Last price₹1,880.00
- Support₹1,846.00−1.81%2 touches, last on March 11, 2026
- Support₹1,817.87−3.30%3 touches, last on September 15, 2026
- Support₹1,754.20−6.69%3 touches, last on June 3, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 18.7%
- Largest fall in the last year
- −13.23%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Sun Pharmaceutical Industries: seasonality
Average monthly price change over 31 years
Over the last 31 years, the strongest month for Sun Pharmaceutical Industries has been July: +5.34% on average, positive in 24 years out of 31. The weakest has been May: −0.19% on average, positive in 14 years out of 31. November, the current month, has been positive in 18 years out of 30 (+2.20% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.98% | +1.25% | 18 of 30 |
| February | +2.78% | +1.13% | 17 of 31 |
| March | +4.14% | +2.09% | 21 of 31 |
| April | +2.98% | +2.91% | 22 of 31 |
| May | −0.19% | −1.25% | 14 of 31 |
| June | +1.56% | +0.05% | 16 of 31 |
| July | +5.34% | +6.43% | 24 of 31 |
| August | +3.90% | +1.34% | 17 of 31 |
| September | +2.41% | +1.17% | 19 of 31 |
| October | +0.67% | −0.20% | 15 of 31 |
| November | +2.20% | +2.56% | 18 of 30 |
| December | +1.52% | +2.76% | 17 of 30 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Sun Pharmaceutical Industries and its competitors
Its tablets, capsules, injectables, inhalers and creams reach patients through a portfolio spanning neuropsychiatry, cardiology, diabetes, gastroenterology and oncology, among other areas. Alongside prescription medicines, the group sells over-the-counter vitamins, analgesics and digestive products, as well as antiretroviral drugs, peptides and steroids. It also supplies active pharmaceutical ingredients and generics for anti-cancer, immunosuppressant and controlled-substance medicines, with operations in India, the United States and other international markets.
- Headquarters
- Mumbai, India
- Employees
- 47,000
- Founded
- 1983
- Chief executive
- Kirti Ganorkar
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Sun Pharmaceutical IndustriesSUNPHARMA | $47.94B | 23.3% | 40.9 | +3.02% |
| Jiangsu Hengrui Pharmaceuticals600276 | $47.86B | 27.4% | 35.9 | −11.86% |
| Takeda Pharmaceutical4502 | $65.79B | 16.6% | 253.2 | +31.34% |
| Divi's LaboratoriesDIVISLAB | $31.67B | 34.0% | 88.0 | +64.93% |
| Hansoh Pharmaceutical Group3692 | $25.82B | 37.3% | 27.6 | −5.09% |
| Torrent PharmaceuticalsTORNTPHARM | $19B | 22.2% | 78.9 | +5.97% |
Same industry or related industries, similar size. Compare Sun Pharmaceutical Industries with its competitors · Full profile
More on Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries revenue and financials
- Sun Pharmaceutical Industries dividend and valuation
- Sun Pharmaceutical Industries stock return
- Sun Pharmaceutical Industries employees, headquarters and business
